Advancing Purification for Complex Biologics
At ChromaGenix™, we help biopharma innovators overcome some of the most persistent challenges in drug development: how to purify complex biologics such as AAVs, mRNA, and viral vectors, more efficiently, consistently, and at scale.
We specialize in developing synthetic affinity ligands and chromatography resins that are engineered for the production of advanced therapies. Whether you’re working on gene therapy, vaccines, or emerging modalities, ChromaGenix is committed to solving your critical downstream challenges, backed by a culture of innovation, integrity, and scientific rigor.
Purification Technologies for the Next Era of Biomanufacturing
ChromaGenix combines proven purification chemistry with investment, a new GMP facility, and a growing portfolio of high-performance tools. We also maintain a deep research partnership with NC State University for the ongoing development of novel, peptide-based affinity ligands to meet the evolving demands of modern bioprocessing.
Our Team
Scientific Advisory Board
Daniel G. Bracewell is Professor of Bioprocess Analysis at the UCL Department of Biochemical Engineering. His notable contributions have significantly advanced our understanding of biological product purification, often through collaborations with industry leaders. He has authored over 100 peer-reviewed journal articles, many of which involve fruitful partnerships with esteemed institutions in Thailand, India, and the USA. Currently, he oversees 15 doctoral and postdoctoral projects.
One particularly impactful project led to the creation of Puridify, a nanofiber adsorption technology company now owned by Cytiva. As the academic lead for the UCL-Cytiva Centre of Excellence, Daniel is at the forefront of pioneering efforts in bioprocessing. His current focus involves the development of cell-free / enzymatic manufacturing technologies and separations for gene delivery vectors, aimed at facilitating targeted healthcare.
Dr. Menegatti is a Professor and Faculty Scholar in the Department of Chemical and Biomolecular Engineering at NC State University and co-founder of the North Carolina Viral Vector Initiative in Research and Learning (NC-VVIRAL).
Dr. Menegatti’s main interests are in purification processes and analytical technologies dedicated to biological therapeutics. His group introduced the paradigm of “flow-through affinity chromatography” and a number of affinity ligands for the purification of proteins, viral vectors, and cells, and has authored over 120 papers and 20 patents.